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Abstract
Background: Different dietary approaches, such as gluten and casein free diets, or the use of probiotics and prebiotics
have been suggested in autistic spectrum disorders in order to reduce gastrointestinal (GI) disturbances. GI symptoms
are of particular interest in this population due to prevalence and correlation with the severity of behavioural traits.
Nowadays, there is lack of strong evidence about the effect of dietary interventions on these problems, particularly
prebiotics. Therefore, we assessed the impact of exclusion diets and a 6-week Bimuno® galactooligosaccharide (B-GOS®)
prebiotic intervention in 30 autistic children.
Results: The results showed that children on exclusion diets reported significantly lower scores of abdominal pain and
bowel movement, as well as lower abundance of Bifidobacterium spp. and Veillonellaceae family, but higher presence
of Faecalibacterium prausnitzii and Bacteroides spp. In addition, significant correlations were found between bacterial
populations and faecal amino acids in this group, compared to children following an unrestricted diet. Following B-
GOS® intervention, we observed improvements in anti-social behaviour, significant increase of Lachnospiraceae family,
and significant changes in faecal and urine metabolites.
Conclusions: To our knowledge, this is the first study where the effect of exclusion diets and prebiotics has been
evaluated in autism, showing potential beneficial effects. A combined dietary approach resulted in significant changes
in gut microbiota composition and metabolism suggesting that multiple interventions might be more relevant for the
improvement of these aspects as well as psychological traits.
Trial registration: NCT02720900; registered in November 2015.
Keywords: Autism, GOS, Microbiota, Prebiotics, Gut symptoms, Sequencing, 1H-NMR
Background
Autism is a neurodevelopmental disorder characterised
by impaired social interaction, verbal and non-verbal
communication, and repetitive behaviour. In addition to
cognitive aspects, autistic spectrum disorder (ASD) indi-
viduals can suffer from gastrointestinal (GI) problems
such as abdominal discomfort, pain and gas distension
[1]. Causes of these gut difficulties are unknown but
have been suggested to involve gut microbiota, in par-
ticular reduced number of bifidobacteria and increased
Clostridium spp., Desulfovibrio spp., Sutterella spp. and/
or Veillonellaceae [2]; altered dietary intake and in-
creased gut permeability [3]. Previous studies reported
alterations in gut barrier function and GI issues in ASD
individuals [4] with the latter often associated with
symptom severity [5]. Adam and colleagues looked at GI
dysfunction as a parameter and noticed a strong correl-
ation between GI symptoms and severity of autism [6].
These results were also confirmed by Tomova et al. in a
more recent study [7].
Exclusion approaches, such as gluten and casein-free
diets (GFCF), have been suggested for their potential
benefits, but to date strong empirical evidence of their
effect on gut health is lacking.
Observational studies reported alleviation of GI prob-
lems and/or improved behavioural traits with GFCF, but
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associations between restricted diet and symptoms are
not always apparent [8–10]. Some studies evaluating
mood and behaviour showed significant improvements
in behavioural traits [11, 12], while others reported no
differences after treatment [13–15].
Human gut microbiota (GM) impacts health and
well-being and is known to be strongly influenced by
diet [16]. A few studies have focused on GM modula-
tors, such as probiotics in ASDs, but there is inconsist-
ency in the parameters evaluated [17, 18]. Parracho et al.
focused on behavioural features, reporting improvement
after Lactobacillus plantarum WCSF1 administration in
ASD children [19], whereas Adam et al. showed signifi-
cant positive differences in faecal organic acid levels in
ASD individuals taking probiotics [6]. Metabolic changes
were also observed by Kaluzna-Czaplinska and Błas-
zczyk [20] who, after 2 months of oral supplementation
with L. acidophilus (strain Rosell-11), found a signifi-
cant decrease in the level of D-arabinitol (DA)-positive
modification cosidering its association with pathogenic
Candida spp. [20].
Further, Tomova and colleagues evaluated the impact of
4 months of mixed probiotic administration (Children
Dophilus) on GM composition in ASD children and they
were able to show modulation of the Bacteroidetes/Firmi-
cutes ratio and an increase in bifidobacterial numbers [7].
Prebiotics are food ingredients selectively metabolised
by indigenous beneficial bacteria thereby positively
modulating GM. Their effects in autism are not well
documented. Previously, we showed that the prebiotic
B-GOS® (a galactooligosaccharide) had an impact on the
faecal microbiota composition and metabolic profile
using an in vitro fermentation system mimicking condi-
tions of the autistic colon [21]. Its impact in vivo, espe-
cially taking into consideration the different dietary
approaches that ASD children might follow, has not
been investigated. Thus, the purpose of this study was to
understand the impact of diet on GM composition and
metabolism in ASD children and to investigate the
modulating potential of B-GOS® intervention on these
paramenters. Additionally, the effect of B-GOS® was
evaluated on GI dysfunction, mood, behaviour, and
sleep. To our knowledge, this is the first study to evalu-
ate prebiotic potential in ASD.
Results
Baseline dietary intake
Food diaries (N = 30) were analysed at baseline (before
starting with the prebiotic intervention) by comparing
daily macronutrient and micronutrient intakes according
to different diets that the children were following (exclu-
sion and unrestricted diet). Significant differences were
seen only in vitamin D intake (Table 1). ASD children
who were on the unrestricted diet had significantly lower
vitamin D consumption compared to ASD children on
exclusion diets (P < 0.01). In addition, vitamin D intake
Table 1 Energy and nutrient intake in children on exclusion and un-restricted diets and comparison with the UK government
recommendations for typically developing children
Exclusion diet Un-restricted diet Typically developed children
Daily dietary composition Mean SD Mean SD Adequate intake
Energy Intake Kcal 1579.18 394.19 1478 578.70 1430–1920
Protein Intake g 56.93 17.30 55.01 15.68 19.7–42.1
Carbohydrate g 183.58 35.20 187.26 74.99 191–333
Total sugars g 63.32 27.58 81.46 36.44 19–33
Fibres g 17.19 5.60 15.36 9.26 17.5–25
Saturated fatty acid g 22.22 12.26 22.28 12.25 17.5–31
PUFA g 12.41 6.39 9.88 7.97 10.5–18
MUFA g 22.88 18.19 19.39 16.76 20.5–36
Vitamin C mg 73.64 44.46 70.94 68.00 30–35
Vitamin D μg 2.72 1.40 1.21** 1.18 10
Vitamin B1 mg 1.38 0.49 1.38 0.66 0.6–1
Vitamin B2 mg 1.44 0.56 1.41 0.64 0.8–1.2
Vitamin B6 mg 1.15 0.33 1.13 0.53 0.9–1.2
Vitamin B12 μg 3.04 1.84 3.82 2.56 0.8–1.2
Iron mg 10.37 4.30 8.04 2.99 6.1–11.3
Calcium mg 536.00 247.89 697.17 357.52 450–1000
Mean average of four consecutive days, SD standard deviation
**P < 0.01
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was much lower, for both groups, than daily UK govern-
ment recommendations (10 μg/day) [19].
GI symptoms and sleep diaries
At baseline, scores extracted from GI symptom diaries
(N = 30) showed that exclusion diets had a significant
impact on gastrointestinal problems (Fig. 1). Significantly
lower scores of abdominal pain (P < 0.05) and bowel
movement (P < 0.001) were reported in children follow-
ing exclusion diets.
GI symptoms were also quantitatively evaluated during
the intervention period (N = 26), and a general trend of
reduction in GI problems was reported after B-GOS® use
(data not shown), but differences between treatments
were not significant. Significant effects were observed
for the interaction between diet and time, for bowel
movements (P < 0.01) and flatulence (P < 0.05). Qualita-
tive analysis performed on sleep habits showed that 23%
of participants (two ASD following unrestricted diet and
one under exclusion diet) benefited from B-GOS® inter-
vention (N = 13). Parents reported that their children
slept 1 h longer than usual and noticed that the children
had less problems falling asleep.
Anxiety and ASD-related behaviour questionnaires
Anxiety and ASD-related behaviour questionnaires (N = 26)
were analysed taking into account age, diet and interven-
tion. The results showed a significant improvement in so-
cial behaviour scores (i.e. scores were lower) after B-GOS®
intervention in ASD children following exclusion diets
(N = 6). Specifically, results from the AQ question-
naire social skills scale (RMANCOVA of T2 and T3
adjusting for T1, diet by treatment interaction,
F(1,21) = 4.62, p < 0.05) mirror improvements in anti-social
behaviour from the ATEC questionnaire (RMANCOVA,
adjusting for age, time by diet by treatment interaction,
F(2,42) = 3.20, p = 0.05). This shows that this aspect of
autistic behaviour varied over time depending on both
exclusion diet and treatment (Fig. 2a, b). No other behav-
ioural measures were significantly affected.
Bacterial composition by FISH analysis
FISH analysis was performed on total bacteria and bifi-
dobacteria of the faecal samples collected at baseline,
after intervention and at follow-up (N = 78). Despite an
increase in the number of Bifidobacterium spp. after
B-GOS intervention (data not shown), FISH results did
not show any significance difference between treatments
and the interaction between treatments versus diet.
Gut microbiota composition as determined by 16S rRNA
gene amplicon sequencing
Baseline
Søresen-Dice distance based principal coordinate analysis
(PCoA, Additional file 1: Figure S1A) showed separation
between volunteers (N = 30) on exclusion and unrestricted
diets at baseline (week 1 and week 2) considering the pres-
ence or absence of particular bacteria (N = 60 samples).
Such separation was not observed on Bray-curtis
distance-based PCoA (Additional file 1: Figure S1B) when
taking also the relative abundance of GM into consider-
ation, indicating that the main GM differences were
driven by variations in the lower abundant bacterial
groups. A redundancy analysis (RDA) model was built to
assess the impact of the variable ‘diets’ on GM compos-
ition (P < 0.004). PCA (principal component analysis)
biplot showed different bacterial groups significantly asso-
ciated with separation (Fig. 3a). Bacteroides spp. (Bacteroi-
daceae), Rikenellaceae, Roseburia spp. (Lachnospiraceae),
F. prausnitzii (Ruminococcaceae) and Clostridiaceae were
present in higher proportion in the exclusion diet
group, whereas Eggerthella lenta, Bifidobacterium spp.
(Coriobaceriaceae), B. fragilis (Bacteroidaceae), Akkermansia
muciphila (Verrucomicrobiacea), Streptococcus anginosus,
Lactococcus spp. (Streptococcaceae), and Dehalobacterium
spp. (Dehalobacteriaceae) were present in higher relative
abundance in the unrestricted diet (Additional file 2:
Table S1). Additionally, bifidobacteria were found in lower
abundances (3.5%; log10 = 8.95 CFU/g) in the exclusion
diet group compared to the unrestricted diet group (4.5%;
log10 = 9.59 CFU/g). Also, a reduction in the Veillonella-
ceae family was observed.
B-GOS® intervention
A significant RDA model (4% variance; P < 0.038) was
identified comparing GM composition from ASD chil-
dren with unrestricted diets, before (baseline; N = 21
Fig. 1 GI symptom assessment during 3 weeks baseline data collection.
S exclusion diets; N unrestricted diet; *P < 0.05; ***P< 0.001
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samples) and after B-GOS administration (N = 21 sam-
ples). Figure 3b shows PCA biplot reporting bacterial
populations positively associated with B-GOS supple-
mentation in ASD children on the unrestricted diet.
These included Bifidobacterium spp., Ruminococcus
spp., Lachnospiraceae family (Coprococcus spp., Dorea
formicigenerans, Oribacterium spp.), Eubacterium dol-
chum, TM7–3 family and Mogibacteriaceae. Addition-
ally, in this intervention group, rarefaction curves
showed that B-GOS® supplementation increased diver-
sity in GM composition, but this increase was not sig-
nificant (Additional file 3: Figure S2).
Significant results (RDA model; 6% variance; P < 0.008)
were identified comparing the effect of treatments (pla-
cebo vs B-GOS®) on gut microbiota composition of ASD
children following exclusion diet after 6 weeks interven-
tion. Additional file 4: Figure S3 shows different GM
profile between the two groups analysed (Additional file 4:
Figure S3A) and the main bacterial populations identi-
fied in the B-GOS® and placebo groups, respectively
(Additional file 4: Figure S3B; abundances above 1%).
Furthermore, Bifidobacterium adolescentis and Bifi-
dobacterium longum were found to be the most
abundant within Bifidobacterium spp., with B. longum
Fig. 2 a ATEC questionnaire. Results showed consistent reduction over time in anti-sociability score in children on the combination of the exclusion
diet and B-GOS intervention, with the most apparent difference occurring at follow-up (time × diet × treatment interaction, p = 0.05; adjusted for age).
Placebo:Maltodextrin. b AQ questionnaire. After intervention and including follow-up, social skills were improved (i.e. scores were lower) by B-GOS
treatment in children on the exclusion diet only (diet × treatment interaction, P < 0.05). Results were reported as estimated marginal means ± standard
error (SE). NB, post-hoc comparisons are not valid where covariates are included
Fig. 3 a PCA plot showing differences in microbial genera based on diet as determined by RDA analysis. b PCA plot displaying differences in microbial
genera after B-GOS treatment in un-restricted diet group as determined by RDA analysis. Blue dots: after B-GOS® intervention; pink dots: before B-GOS®
intervention. X displays the loading positions of the most discriminative bacterial genera
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being significantly predominant in ASD children
under the exclusion diet compared to placebo (P < 0.02;
Additional file 5: Figure S4).
1H-NMR analysis
Baseline
Orthogonal projections to latent structures-discriminant
analysis (OPLS-DA) models were built to assess urinary
and faecal metabolic perturbations induced by the differ-
ent diets and B-GOS intervention. No significant meta-
bolic differences were observed in the OPLS-DA model
comparing urine spectra from ASD children on the two
different diets (Q2 Ŷ = − 0.0199) at baseline (N = 60).
Conversely, comparison of faecal profiles from children
on the exclusion and unrestricted diets (N = 60) revealed
distinct metabolic perturbations (Q2 Ŷ = 0.185, P < 0.001),
at baseline, driven by the diets.
Figure 4a, b summarise correlations between bacterial
changes and metabolic variation in faecal samples of
children following an exclusion diet (N = 24) and those
on an unrestricted diet (N = 36), respectively. During the
exclusion diet (Fig. 4a), Bacteroides spp. (OTU005,
OTU007 and OTU008) strongly correlated with glycerol
and propionate, whereas Bifidobacterium spp. (OTU001)
and Eghertella lenta (OTU004) were positively corre-
lated with valine, leucine and isoleucine. E. lenta was
correlated to lysine and alanine. In faecal samples from
children on the unrestricted diet (Fig. 4b), positive corre-
lations were identified for Eggerthella lenta (OTU004)
and Streptococcus anginosus (OTU011) with lactate,
tyrosine, 2-hydroxy-2-methilbutyrate, isoleucine, leucine,
phenylalanine and valine; for Bacteroides spp. (OTU006,
TOU005 and OTU008) with lactate; for F. prautznii
(OTU016) with glucose; and for Coprobacillus spp.
(OTU017) with 2-hydroxy-2-methilbutyrate.
Intervention
Intervention with B-GOS® led to significant alterations in
the urine spectra profiles of ASD children following unre-
stricted diets (N = 42), indicating that B-GOS® supplemen-
tation contributed to metabolic variation. A significant
OPLS-DA model (Q2 Ŷ = 0.065; R2 Ŷ = 0.13; P < 0.001)
was obtained by comparing metabolic profiles of ASD
children taking placebo and those taking B-GOS®, after
6 weeks of intervention (Additional file 6: Figure S5).
Urine spectra of autistic volunteers receiving B-GOS
treatment contained greater amounts of creatinine,
creatine, dimethylglycine (DMG), dimethylalanine (DMA),
carnitine, citrate, adipate and trimethylamine-N-oxide
(TMAO) compared to the autistic children taking placebo.
In addition, B-GOS supplementation seemed to reduce
amounts of phenylacetylglycine (PAG), phenylalanine and
β-hydroxybutyrate in the test intervention group.
Metabolic shifts were also observed in faecal samples
after B-GOS® intervention. At baseline (N = 28), a nega-
tive Q2 Ŷ was associated with ASD children on unre-
stricted diets (Q2 Ŷ = − 0.3632), but after B-GOS®
supplementation (N = 42), a significant OPLS-DA model
was obtained (Q2 Ŷ = 0.2997, P < 0.001). Ethanol, DMG
and SCFAs (butyrate, valerate) were positively correlated
with B-GOS® intake. Increases in butyrate production
were also detected in ASD children following exclusion
diets; however, these changes were not significant (data
not shown). In addition, lower levels of amino acids (iso-
leucine, leucine, valine, alanine, glutamine) and lactate
were detected in the B-GOS® group, compared to
placebo (Additional file 7: Figure S6).
Discussion
This is the first time that the impact of diet on GM
composition and metabolism, their potential association
with GI discomfort and the effect of a prebiotic supple-
mentation has been investigated, in the context of
autism. Significant differences, in both microbiota and
metabolism, were detected at baseline when a compari-
son between the diets was performed. This could mean
that diet has an impact on the gut environment. In
addition, significant improvements in behavioural traits
after B-GOS® supplementation, in ASD children follow-
ing an exclusion diet, could indicate that combined
interventions might be more beneficial in ASD individ-
uals than a single dietary approach.
Before prebiotic B-GOS® intervention, we evaluated the
nutritional impact of exclusion diets (GFCF) and our re-
sults showed deficiency in vitamin D intake, which was
significant in children on unrestricted diets. These find-
ings are supported by recent studies conducted in Spain,
where an autistic group under a restricted diet (n = 105)
consumed fewer carbohydrates (reported also in our
study) and had higher consumption of legumes and vege-
tables [22, 23]. An interesting aspect from these studies,
including ours, was the consistent identification of low
vitamin D intake. Vitamin D is considered an active neu-
rosteroid during brain development, and its deficiency has
been suggested as a potential environmental risk factor for
ASD [24–26]. Therefore, the association between ASD
and Vitamin D deficiency warrants further investigation.
In addition to nutritional status, previous studies in
ASD tended to evaluate the impact of exclusion diet on
GI symptoms or behaviour, showing inconsistent results
[27]. The hypothesis behind use of this diet is the so
called ‘opioid excess theory’. This suggests that gluten
and casein metabolism results in excessive production of
opioid compounds causing side effects, such as constipa-
tion and behavioural problems [28]. Therefore, exclusion
diets have been hypothesised to alleviate such issues but
our study showed, in both restricted and unrestricted
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diets, that abdominal pain scores were below one. This
means that GI dysfunctions were present but well toler-
ated in both groups, despite the significant difference
observed, suggesting that the exclusion diet should not
be considered a definitive solution for GI discomfort.
Furthermore, recent randomised trials showed that ASD
individuals tolerated gluten and casein introduction into
their diet, questioning GFCF diet efficacy [29, 30].
Currently, metagenomic analyses in autism mainly
focuses on identifying potential biomarkers in gut bac-
terial composition, usually comparing faecal samples
from autistic individuals with siblings and non-autistic
controls [31–33]. Results from these studies have identi-
fied several genera present in higher abundance in ASD,
such as Bacteroides, Roseburia, Akkermansia, Hespellia
spp., and others in lower abundance, such as Prevotella
and bifidobacteria [34, 35].
There are no studies evaluating the effect of GFCF
dietary approaches on GM in ASD individuals; therefore,
our focus was to understand the impact of this diet on
gut bacterial composition and metabolism. Our observa-
tions showed that volunteers following exclusion diets
had lower abundances of bifidobacteria and Veillonella-
ceae, as previously reported in healthy adults [36]. These
findings suggest that dietary restriction might have
bigger impact on the growth of these bacterial groups,
than type of disorder (e.g. autistic features).
In addition, metabolomic analyses showed amino acids
(AA) to be the main metabolites present in faecal sam-
ples from both dietary groups, as seen previously [37].
This could be due to malabsorbtion of nutrients, since
results obtained from the food diaries showed increase
in protein and total sugar intake. These outcomes sup-
port the hypothesis that exclusion diet alone might not
be enough to improve gut health.
Correlograms built in our analyses using bacterial
composition and metabolites confirmed that bacterial
groups such as Clostridium spp., Bacillus spp., Lactoba-
cillus spp., and Streptococcus spp., are associated with
AA metabolism [38]. It is known that AA are precursors
for neurotransmitters, such as tryptophan for serotonin
or tyrosine for catecholamines, but little is known on the
impact of GM in these pathways and how diet might
modulate it [39].
Our results also showed strong correlations between
Bacteroides spp. and propionate in faecal samples of
ASD children on exclusion diets. SCFAs have been
shown to affect the CNS and in particular, intraventricu-
lar injection of propionate in mice has been seen to
cause autistic like behaviour [40]. Our data show the po-
tential role of the GM in the production of metabolites
that might be associated with autistic traits. However,
the actual impact of SCFAs produced in the gut on CNS
needs to be further elucidated, since the concentrations
that might pass through the blood-brain barrier (BBB)
may be small.
Overall, our data following B-GOS® intervention did
not show a significant impact on GI symptoms and
sleep, even though a trend of reduction of GI discom-
forts was observed (data not shown). The reason for this
might in part be due to various difficulties reported by
the parents in evaluating these aspects and related to
impediments in communication skills that are typical of
ASD children.
Combining B-GOS® treatment with the exclusion diet
showed a significant reduction in anti-sociability scores,
supporting the hypothesis that combined intervention
therapies might have a better impact on such psycho-
logical traits. This is the first study to show a synergistic
effect between exclusion diet and a prebiotic interven-
tion and the results are promising. Interestingly, even
though no significant differences were reported over
time between baseline and prebiotic intervention in this
group (data not shown), significant changes were de-
tected in the gut microbiota composition of ASD chil-
dren following exclusion diet when variable ‘treatment’
(placebo against B-GOS®) was analysed after 6 weeks of
intervention. In addition, in this intervention group (ex-
clusion diet + B-GOS®), significantly higher abundance
of B. longum was observed, matching previous results
reported in a recent human intervention study [41],
where administration of B. longum 1714 reduced stress
and improved memory [41]. These results strengthen
the potential beneficial role of these bacteria on CNS
and impact of these combined dietary approaches.
To our knowledge, this is the first study where 16S
rRNA gene amplicon sequencing has been used to better
understand the impact of a prebiotic intervention on
GM in autism. B-GOS was able to modulate the GM
composition in autistic children on unrestricted diets,
modulating bifidobacterial changes as well as in other
bacterial groups, such as Lachnospiraceae family (Copro-
coccus spp., Dorea formicigenerans, Oribacterium spp.),
known to be butyrate-producing bacteria. Mego and
(See figure on previous page.)
Fig. 4 Summary of the correlation between bacterial changes and metabolic variation in faecal samples of children following exclusion diet a and those
in un-restricted diet b. OUTs: bacterial groups. Arrows: metabolites identified; Squares: bacteria involved in the metabolic pathway. OTU001: Bifidobacterium
spp.; OUT002: Bifidobacterium longum; OTU003: Coriobacteriaceae; OTU004: Eggerthella lenta; OTU005: Bacteroides spp.; OTU006: B. fragilis; OTU007: B. ovatus;
OTU008: B. uniformis; OTU009: Rikenellaceae spp.; OTU010: Lactococcus spp.; OTU011: Streptococcus arginosus; OTU012: Clostridiales; OUT013: Clostridiaceae;
OTU014: Dehalobacterium spp.; OTU015: Roseburia spp., OTU016: F. prausnitzii; OTU017: Coprobacillus spp.; OTU018: Akkermansia muciphila
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colleagues reported the same results in a human inter-
vention study in healthy adults where regular consump-
tion of B-GOS® treatment-induced changes in the gut
microbiota, and its modulation was correlated with
reduced gas production [42].
We supported these results by 1H-NMR metabolomics,
detecting butyrate as main SCFAs produced and matching
our previous in vitro data, where B-GOS supplementation
modulated bacterial and metabolic changes in ASD [21].
It has been shown, in cell culture studies, that butyrate
regulates tyrosine hydroxylase (TH) mRNA levels and
consequently may affect catecholamine pathway in the
brain [43–47], thus potentially positively impacting ASD
[48]. Therefore, showing that B-GOS was able to stimulate
butyrate production in ASD in vitro and in vivo suggests
that it could have an indirect effect on the CNS through
modulation of gut bacterial populations.
Interestingly, we also observed a reduction of AA in
faecal samples of ASD children taking B-GOS®. The
presence of these compounds in faeces has been previ-
ously associated with problems in gut barrier function
which could lead to malabsobtion of dietary compo-
nents, typical of disorders related to gut inflammation,
such as Inflammatory Bowel Disease (IBD) [49]. There-
fore, decreasing AA excretion suggests that B-GOS® sup-
plementation could help to improve gut health. This
could be associated with butyrate production, which in-
creased after B-GOS® intervention, since improvements
in barrier functions have been previously detected in
vitro with sodium butyrate [50].
Some confounding factors might impact the analysis
of urine samples, such as medication, diet and lifestyle.
These are difficult to control, especially when the sample
size is small; even though diet and medication intake
were recorded during the study. Significant correlations
were identified in ASD children under unrestricted diets
between citrate, creatine, creatinine and B-GOS®. Incon-
sistent levels of creatinine have been detected in ASD
individuals and are considered as potential biomarkers
for creatine deficiency syndrome (CDS), a metabolic
disorder with similar features to autism [51]. In addition,
they have been considered as biomarkers for other brain
disorders such as Alzheimer’s disease [52] and schizo-
phrenia [53], so it would be interesting to have a deeper
understanding of implications for ASD.
Conclusions
In summary, this was the first trial to assess the impact
of exclusion diets and a prebiotic intervention on GM
composition and metabolic activity in ASD. The study
showed a significant impact of diets on GM. An exclu-
sion diet resulted in a high AA excretion and potential
problem in nutrient malabsorption, suggesting that it
should be reconsidered as first dietary intervention to
improve gut issues. A combined dietary approach of a
prebiotic and exclusion diet, resulted in a significant im-
provement in antisocial behaviour suggesting that such
approaches might be more relevant for improvement of
these aspects as well as psychological traits.
Methods
Study design
A randomised, double-blind, placebo-controlled (Malto-
dextrin—GLUCIDEX®; 1.8 g), parallel-designed prebiotic
B-GOS® mixture (Bimuno®; 1.8 g: 80% GOS content)
feeding study was conducted in children diagnosed with
ASD. Both treatments were provided in powder form
and supplied by Clasado Biosciences Ltd. (Reading, UK).
The study was conducted according to the guidelines of
the Declaration of Helsinki, and the University of Read-
ing Research Ethics Committee (UREC15/41) approved
all procedures involving human subjects.
Subjects
A total of 41 autistic children (31 male and 10 female;
mean age 7.7 years old; range 4–11 years) with formal
diagnosis of ASD were enrolled in the study (Fig. 5) in
order to have a 95% probability that the study would
detect, at a two-sided 5% significance level, a significant
effect on the colonic bifidobacterial population. Of these
41, 11 subjects withdrew from the study during the base-
line period, largely due to difficulties and/or inconve-
niences associated with collecting samples. The remaining
30 volunteers were divided into two groups A and B,
according to dietary habits assessed by 4-day food diaries,
children whose diet was not restricted (n = 18) and on
exclusion diet (n = 12), mainly gluten and casein free.
Within these groups, children were randomly assigned to
two feeding groups using a random number system.
Group I received placebo and group II received B-GOS®
during the 6-week feeding period. However, four subjects
subsequently dropped out before the end of the first feed-
ing arm. One left the study without giving a reason, two
were withdrawn due to protocol violation, and one
withdrew due to an adverse event (strong diarrhoea and
abdominal pain observed after 2 days of treatment feed-
ing). In total, 26 volunteers completed the 10-week study
providing 80% statistical power. Volunteers were assessed
before the start of the trial and were selected according to
certain exclusion and inclusion criteria. Inclusion criteria
for participation in the study were signed consent form
from volunteers’ parents or guardians, age of 4–11 years
inclusive, formal diagnosis of ASD (severity was not taken
into consideration; Table 2). Exclusion criteria involved
the use of probiotics, prebiotics, antibiotics, or other diet-
ary supplement drugs that could affect the luminal micro-
environment of the intestine, within 4 weeks before the
study, were also excluded. Volunteers were instructed not
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to consume such products during the study and not to
alter their usual diet or fluid intake. Volunteers were
required to visit the University of Reading or the re-
searcher visited the volunteers at home on five separate
occasions during the study period in order to provide fae-
cal and urine samples (weekly collection).
Dietary intervention and assessments
Food diary records were kept for four consecutive days
during the baseline period. Before starting with the
intervention, food diaries were discussed with parents in
order to monitor compliance. At the front of the diary,
detailed information on how to record food and bever-
ages consumed using common household measures were
provided. Food diaries were analysed using Diet-plan7
software (Forestfield Software Ltd.)
GI symptoms
Parents/guardians of child volunteers were asked to fill in
daily questionnaires for GI function and symptoms. The
Bristol stool chart was used to assess faecal sample type
and consistency, together with the number of bowel move-
ments, abdominal pain, intestinal bloating and flatulence
[54]. Concomitant medication, adverse events, changes in
diet and behaviour were also recorded throughout the
study, on separate sample submission forms.
Behavioural and sleep assessment
Parents/guardians were asked to complete an Autism
Treatment Evaluation Checklist (ATEC; [55]) to evaluate
effectiveness of treatment; autism spectrum quotient
(AQ; [56]) in order to assess the autism symptoms; em-
pathy and systemising quotient (EQ-SQ; [57]) to assess
the capacity of the child to understand emotions and
thoughts and how to process them; and Spence’s Chil-
dren Anxiety Scale-Parent version (SCAS-P; [58]) in
order to identify levels of anxiety. In addition, parents/
guardians were asked to complete 5-day sleep diaries be-
fore (baseline) and after intervention (during last week
Table 2 Diagnosis (*) reported from parents by medical
assessment
Diagnosis* ASD ADHD Asperger PDD
Volunteers (n) 26 5 1 1
Exclusion diet
B-GOS (B-II)
6 1
Exclusion diet
Placebo (B-I)
6 3 1
Un-restricted diet
B-GOS (A-II)
7 1
Un-restricted diet
Placebo (A-I)
7 1
All participants were diagnosed with ASD (n = 26) and some volunteers also
had additional diagnoses (ADHD, Asperger, PDD)
ASD autism spectrum disorders, ADHD attention deficit hyperactivity disorder,
PDD pervasive development disorder
Fig. 5 Study information. a Flow of participants through the study. b Study design
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of the intervention period) in order to understand the
qualitative impact of B-GOS supplementation on sleep
disorder, if present.
Faecal sample collection and preparation
Faecal samples were collected once a week using a faecal
collection kit (FC2040, Laboratories Ltd., UK), and volun-
teers were asked to keep them at − 20 °C until the visit
day, when they were transferred to the laboratory and
processed. Samples for DNA extraction and 1H-NMR
were weighed (~ 250 mg) and stored at − 80 °C until
needed for analysis.
Urine sample collection and preparation
Urine samples were collected once a week using sterile
tubes (Mid-Stream Urine Specimen Collector; Pennine
Healthcare, UK) or sterile pads (Sterisets Urine Collec-
tion Kit; MediBargains, UK) and stored at − 20 °C until a
visit day when they were processed. Samples were trans-
ferred to 15-ml falcon tubes, centrifuged for 10 min at
1136×g, supernatant transferred to 1.5-ml Eppendorf
tube (duplicate) and stored at − 80 °C.
DNA extraction
Total microbial DNA was extracted from faeces using the
DNA stool mini kit (Qiagen, UK) by introducing three
1-min steps at 50 movements/s using TyssueLyser LT
(Qiagen, UK) with 5-min incubation in ice between treat-
ments as previously described by Candela et al. 2016 [59].
DNA recovery was evaluated using a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies).
Fluorescence in situ hybridisation (FISH)
Synthetic oligonucleotide probes targeting specific re-
gions of the 16S rRNA labelled with the fluorescent dye
Cy3, as previously described by Grimaldi et al. 2016 [60],
were used for bacterial enumeration assessed by FISH
analysis. The probes used (Eurofins Genomics, UK) were
Bif164 for Bifidobacterium spp. [61] and EUB338 I-II-III
[62]. EUB338 I-II-III probe was used to calculate total
bacterial numbers. This value was multiplied by the
abundances (%) of each bacterial group obtained from
the 16S sequencing analysis and then converted in
Log10. Bif164 probe has been used to evaluate the bifido-
genic activity of the prebiotic product due to its high
specificity for bifidobacterial group.
16S rRNA gene amplification via next-generation
sequencing (NGS) and bioinformatics analysis
For each sample, the V3–V4 region of the 16S rRNA
gene was PCR-amplified in 25 μl volumes containing
12.5 ng of microbial DNA, 2× KAPA HiFi HotStart
ReadyMix (Kapa Biosystems, USA) and 200 nmol/l of
S-D-Bact-0341-b-192S-17/ S-D-Bact-0785-a-A-21 primers
carrying Illumina overhang adapter sequences (Bio-Fab Re-
search). Thermal cycling consisted of an initial denaturation
at 95 °C for 3 min, 25 cycles of denaturation at 95 °C for
30 s, annealing at 55 °C for 30 s, extension at 72 °C for 30 s
and a final extension step at 72 °C for 5 min. Amplicons of
440 bp were purified with a magnetic bead-based clean-up
system (Agencourt AMPure XP; Beckman Coulter) and
sequenced on Illumina MiSeq platform using a 2 × 250 bp
paired end protocol, according to the manufacturer’s in-
structions (Illumina, San Diego, CA). Libraries were pooled
at equimolar concentrations, denatured and diluted to
4 nmol/l. Pair-ended amplicon reads (with corresponding
quality scores) were trimmed, merged, clustered (op-
erational taxonomic units [OTU] with 97% similarity),
filtered from chimeric sequences using UPARSE [63]
and taxonomically assigned using the GreenGenes
database (version 12.10) [64]. For downstream analysis,
the OTU-table was normalised with cumulative sum scal-
ing (CSS) [65] using the Qiime toolbox (v1.9) [66]. Data
from volunteers were pooled together during the analysis,
and only the samples at baseline (weeks 1 and 2), after
treatment (weeks 6, 7 and 8) and follow up (weeks 9 and
10) were considered for the analysis. Beta-diversity was
assessed through Bray-Curtis and Søresen-Dice distances
and the factor-treatment analysed with redundancy ana-
lysis (RDA) [67]. Alpha-diversity was measured and
expressed as observed species (97% similarity OTUs) and
computed with 10 rarefied OTU tables. Comparison of
Alpha-diversities was made through nonparametric t-test
method (Monte Carlo, 999 permutations).
Metabolic analysis by 1H-NMR
Four hundred microliters of urine samples were
combined with 200 μL of phosphate buffer [0.2 M (pH
7.4) in D2O plus 0.001% TSP (3-(trimethylsi-
lyl)-[2,2,3,3,−2H4]-propionic acid, δ 0.00)], mixed by
vortexing, centrifuged at 1136×g for 10 min, and then
550 μL was transferred into 5 mm NMR tubes for ana-
lysis. Faecal samples were pre-weighed (250 mg) and
700 μL of phosphate buffer and 2 glass beads added in
order to perform a bead-beating 5 min step at 25
movements/s using TyssueLyser LT (Qiagen, UK). Then,
500 μL was transferred into 5-mm NMR tubes for ana-
lysis. All NMR spectra were acquired on a Bruker
Avance DRX 500 MHz NMR spectrometer (Bruker
Biopsin, Rheinstetten, Germany) operating at 500 MHz.
They were acquired using a standard one-dimensional
(1D) pulse sequence [recycle delay (RD)–90°–t1–90°–tm–
90°-acquire free induction decay (FID)] with water sup-
pression applied during RD of 2 s, a mixing time Tm of
100 ms and a 90 pulse set at 7.70 μs. For each spectrum, a
total of 128 scans were accumulated into 64 k data points
with a spectral width of 12.001 ppm. The FIDs were
Grimaldi et al. Microbiome  (2018) 6:133 Page 10 of 13
multiplied by an exponential function corresponding to
0.5 Hz line broadening.
Data preprocessing and analysis
Data from volunteers were pooled together during the
analysis. Samples at baseline (weeks 1 and week 2),
after treatment (weeks 6, 7 and 8) and follow-up (weeks
9 and 10) were considered for the analysis. All spectra
were manually phased, baseline corrected and cali-
brated to the chemical shift of TSP using TopSpin
(Bruker Biopsin, Rheinstetten, Germany). Spectra were
digitised using an in-house MATLAB (version R2014a,
The Mathworks, Inc.; Natwick, MA, USA), and median
fold normalisation was performed. The spectral region
containing the water resonance was removed to minim-
ise distortions in the baseline arising from imperfect
water saturation. Principal component analysis (PCA)
using mean-centred data was applied and orthogonal
projection to latent structure discriminant analysis
(OPLS-DA) models were constructed using for pairwise
comparisons of the different experimental groups and
time points. Colour represents the significance of
correlation (r) for each metabolite to class membership.
Predictive strength (Q2 Ŷ) of the models was obtained
using a sevenfold cross-validation method and vali-
dated using permutation testing (number of permuta-
tions = 1000).
Statistical analysis
Behavioural assessments and GI symptoms were ana-
lysed using SPSS software v.22 (SPSS Inc., Chicago, IL,
USA). Mood and behavioural questionnaire analyses
were performed considering the single scale scores and
total score, for each time point (before T1, after treat-
ment T2 and follow-up T3). One-way ANCOVA was
used in order to test whether T2 scores differed between
treatment groups, adjusting for baseline T1 scores as co-
variate. GLM 2 × 2 × 3 RMANOVAs were used to test
whether there were any diet by treatment by time inter-
actions across time points. Each of those RMANOVAs
was followed by a 2 × 2 × 2 RMANCOVA to test for any
diet by treatment by time interactions across T2 and T3
adjusting for baseline (T1) differences (post hoc tests are
not valid where covariates are included); age was in-
cluded as a covariate when significant since some assess-
ments may vary by age. This test was used in order to
assess whether any treatment effect was consistent. GI
symptoms were analysed using a linear mixed model.
The fixed terms assessed in this model were diet, treat-
ment, time (pre-treatment, during treatment, follow-up),
weeks, diet × time, treatment × time and volunteer
scores as a random effect.
Statistical test for food intake records was performed
using Graphad Prism (version 5.0; Graph-Pad Software,
188 La Jolla, CA, USA). Normality test was used to as-
sess whether the data were parametric or not parametric
and unpaired Student’s t test and Mann-Whitney tests
(Bonferroni post-test with significance set at P < 0·05)
were performed respectively on food diary data set in
order to assess statistical differences between exclusion
and un-restricted diets.
Additional files
Additional file 1: Figure S1. Comparison of the gut microbiota
composition between ASD children following exclusion diet and ASD
children following unrestricted diet. (A) Sørensen-Dice distance based
PCoA; (B) Bray-Curtis distance based PCoA. Red dots: exclusion diet; green
dots: unrestricted diet. (JPG 51 kb)
Additional file 2: Table S1. Bacterial groups (Log10) significantly
associated with separation in RDA model (P < 0.004). (DOCX 15 kb)
Additional file 3: Figure S2. Comparison of bacterial richness and diversity
before and after B-GOS treatment in ASD children following unrestricted diet.
Rarefaction curves and box plots showed that B-GOS supplementation
increased the diversity in gut microbial composition of ASD children in
unrestricted diet. (JPG 83 kb)
Additional file 4: Figure S3. (A) RDA model showing the separation
between samples from ASD children following exclusion diet after the
intervention (placebo vs B-GOS®). Blue dots: samples from children taking
placebo; Pink dots: samples from children taking B-GOS®. (B) Bar chart of
the most abundant bacteria in ASD children following exclusion diet
after intervention (placebo vs B-GOS®; bacterial abundances above 1%).
(JPG 174 kb)
Additional file 5: Figure S4. Analysis of the most abundant Bifidobacterium
spp. using 16S rRNA sequencing. (1) before B-GOS®; (2) after B-GOS®; (3) before
placebo; (4) after placebo; (5) unrestricted diet before B-GOS®; (6) unrestricted
diet after B-GOS®; (7) unrestricted diet before placebo; (8) unrestricted
diet after placebo; (9) exclusion diet before B-GOS®; (10) exclusion diet
after B-GOS®; (11) exclusion diet before placebo; (12) exclusion diet after
placebo. *P < 0.05. (JPG 65 kb)
Additional file 6: Figure S5. OPLS-DA obtained comparing the metabolic
profile in urine samples of ASD children in unrestricted diet taking B-GOS® to
those taking placebo. Compounds identified: dimethylglycine (DMG);
dimenthylalanine (DMA); creatinine; creatine; PAG (Phenylacetilglycine); cartine;
malonate; TMAO (trimethylamine-N-oxide); citrate; adipate; beta-hydroxybutyrate;
phenylalanine. (JPG 79 kb)
Additional file 7: Figure S6. OPLS-DA obtained comparing the metabolic
profile in faecal samples of ASD children in unrestricted diet taking B-GOS to
those taking placebo. Compounds identified: dimethylglycine (DMG);
glutamate; butyrate; valerate; ethanol; alanine; lactate; isoleucine; leucine;
valine; uracil; phenylalanine; tyrosine. (PNG 100 kb)
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